

# Press Release

For further information:

Peter Friedli  
Neuhofstrasse 8  
8834 Schindellegi  
Tel: 044/283 29 00  
Email: peter.friedli@friedlicorp.ch

## New Venturetec with a gain for the period October 1, 2010 to March 31, 2011

### **Results for the six months period ending March 31, 2011**

Zug, May 19, 2011. New Venturetec closed the first six months for fiscal year 2010/11, ended March 31, 2011, with a gain of USD 2,684,420 compared with a gain of USD 4,830,258 in the same period 2009/10. The net asset value per share increased from USD 6.83 to USD 7.36 which equals 7.8% during the reporting six month period. The share price in the same period decreased from CHF 4.00 to CHF 3.10, or -22.5%.

The reasons for the profit are the higher valuations of the portfolio companies Etex Corporation, mPortal and Invenda. The share price of Osiris Therapeutics did not change materially in the reporting period. The valuation of the remaining portfolio companies did not change in the reporting period. The details on the valuation of the privately held companies are described in the semi-annual report.

As of March 31, 2011, New Venturetec had six investments with three investments valued higher than the investment costs and three below investment costs. The total value of investments is USD 57,402,529 which results in an unrealized loss of USD 36,504,427 against the costs of the investments. As of March 31, 2011, 69.0% of the total investments are in biotechnology and 31.0% in technology. The largest position is Osiris Therapeutics (NASDAQ:OSIR) with 52.53% of total investments.

There was no board remuneration paid for the reporting period but rather accrued. The management fee for the reporting period was USD 132,112 of which USD 22,471 were paid. Total operational costs for the first half of the fiscal year 2010/11 were USD 166,536.

The semi-annual report, including financial statements for the reporting period can be downloaded from [www.newventuretec.com/pdf-reports/Semi-AnnualReport2011.pdf](http://www.newventuretec.com/pdf-reports/Semi-AnnualReport2011.pdf).

New Venturetec is a publicly traded Swiss investment company (SIX:NEV) which invests directly in venture capital companies predominantly in the USA in the areas of biotechnology and technology.